New combo aims to fight recurrent brain tumors

NCT ID NCT05345002

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs—all-trans retinoic acid (ATRA) and retifanlimab—in 55 people with recurrent IDH-mutant glioma, a type of brain tumor. The goal is to see if the combo can shrink tumors or slow their growth. Participants take ATRA pills for 14 days each cycle and get retifanlimab infusions every 28 days, continuing until the disease worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
All-trans retinoic acid (ATRA) and retifanlimab (a PD-1 inhibitor)
What this could lead to
If it works, this could offer a new treatment option for people with recurrent IDH-mutant glioma, potentially shrinking tumors and delaying progression.
What could go wrong
This is a small, early-phase trial (55 people) with no control group. The combination may not work better than existing treatments, and side effects from immunotherapy and ATRA could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.